Prot# PXD101-CLN-5: A Phase IB/II Safety, Pharmacokinetic, Pharmacodynamic and Anti-Tumor Activity Study of PXD101 in Combination with Bortezomib in Patients with Relapsed, Refractory Multiple Myeloma

Project: Research project

Project Details

StatusFinished
Effective start/end date1/5/063/1/12

Funding

  • Prologue Research International, Inc. (PXD101-CLN-5)
  • CuraGen Corporation (PXD101-CLN-5)